These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11028858)

  • 1. In vivo study of skin mechanical properties in psoriasis vulgaris.
    Dobrev H
    Acta Derm Venereol; 2000; 80(4):263-6. PubMed ID: 11028858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.
    Yamamoto T; Nishioka K
    Skin Pharmacol Appl Skin Physiol; 2003; 16(1):50-8. PubMed ID: 12566829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moisturisers for psoriatic skin--do gross morphological differences matter?
    Kynemund L; Jemec GB; Wulf HC
    Skin Pharmacol Appl Skin Physiol; 2001; 14(1):20-6. PubMed ID: 11174087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The response of uninvolved skin of patients with psoriasis to single and repeated applications of dithranol cream: an immunohistochemical assessment.
    Swinkels OQ; Prins M; van Vlijmen-Willems IM; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2002; 15(6):385-92. PubMed ID: 12476012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical anthralin therapy for refractory nail psoriasis.
    Yamamoto T; Katayama I; Nishioka K
    J Dermatol; 1998 Apr; 25(4):231-3. PubMed ID: 9609979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cutaneous surface parameters in psoriatic patients.
    Cannavò SP; Guarneri F; Giuffrida R; Aragona E; Guarneri C
    Skin Res Technol; 2017 Feb; 23(1):41-47. PubMed ID: 27270565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of topical corticosteroids and a coal tar preparation on dithranol-induced irritation in patients with psoriasis.
    Swinkels OQ; Kucharekova M; Prins M; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2003; 16(1):12-7. PubMed ID: 12566824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy.
    Wollina U; Schmidt WD; Koch A; Scheibe A; Erfurth F; Fassler D
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1409-13. PubMed ID: 19508501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin.
    Paramsothy Y; Lawrence CM
    Br J Dermatol; 1987 Apr; 116(4):517-9. PubMed ID: 3580286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasound evaluation of clobetasol propionate 0.05% foam application in psoriatic and healthy skin: a pilot study.
    Lacarrubba F; Nardone B; Musumeci ML; Micali G
    Dermatol Ther; 2009 Nov; 22 Suppl 1():S19-21. PubMed ID: 19891687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo quantification of microvessels in clinically uninvolved psoriatic skin and in normal skin.
    Hern S; Mortimer PS
    Br J Dermatol; 2007 Jun; 156(6):1224-9. PubMed ID: 17459047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fumaric acid esters and dithranol on acanthosis and hyperproliferation in psoriasis vulgaris.
    Bacharaçh-Buhles M; Röchling A; el Gammal S; Altmeyer P
    Acta Derm Venereol; 1996 May; 76(3):190-3. PubMed ID: 8800297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of dithranol therapy on clinical status and serum calcitonin concentrations in patients with common psoriasis].
    Bendkowski W; Hadas E; Swietochowska E; Wielkoszyński T; Ostrowska Z; Szapska B
    Pol Merkur Lekarski; 2002 Dec; 13(78):481-3. PubMed ID: 12666446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Urea in combination with dithranol in treating psoriasis vulgaris].
    Przybilla B; Kaudewitz P; Bieber K
    Hautarzt; 1989; 40 Suppl 9():54-7. PubMed ID: 2681078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts remaining elevation of dermal expression levels of CD31.
    Hendriks AG; van de Kerkhof PC; de Jonge CS; Lucas M; Steenbergen W; Seyger MM
    Skin Res Technol; 2015 Aug; 21(3):340-5. PubMed ID: 25534374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of plaque thickness and evaporative water loss in psoriasis with PUVA and dithranol treatment.
    Rogers S
    Clin Exp Dermatol; 1993 Jan; 18(1):21-4. PubMed ID: 8440047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dithranol on neutrophil superoxide generation in patients with psoriasis.
    Kavanagh GM; Burton JL; Donnell VO
    Br J Dermatol; 1996 Feb; 134(2):234-7. PubMed ID: 8746335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin polyamine levels in psoriasis: the effect of dithranol therapy.
    Bohlen P; Grove J; Beya MF; Koch-Weser J; Henry MH; Grosshans E
    Eur J Clin Invest; 1978 Aug; 8(4):215-8. PubMed ID: 100325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dithranol irritation in psoriasis treatment: a study of 68 inpatients.
    Kucharekova M; Lieffers L; van de Kerkhof PC; van der Valk PG
    J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):176-9. PubMed ID: 15752286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of steroid and dithranol therapy on cyclic nucleotides in psoriatic epidermis.
    Saihan EM; Albano J; Burton JL
    Br J Dermatol; 1980 May; 102(5):565-9. PubMed ID: 6248098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.